{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-084053","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2025-08-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.100045+00:00","generated_at":"2026-05-17T09:37:04.920671+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Novavax issues $225M 4.625% convertible notes due 2031, exchanges $148.7M of 2027 notes","bullets":["Issued $225M principal of 4.625% Convertible Senior Notes due 2031; initial conversion price ~$11.14 (27.5% premium).","Exchanged ~$175.3M of new notes for ~$148.7M of existing 5.00% 2027 notes; $49.7M for cash.","Notes mature Sept 1, 2031; interest payable semi-annually; redeemable by company after Sept 5, 2028 if stock >130% of conversion price.","Maximum dilution: 25,743,690 shares upon conversion at max conversion rate $8.74 per share.","Exchange portion unregistered under Section 3(a)(9); shares upon conversion also exempt."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-084053","json":"https://secwatch.observer/filing/0001104659-25-084053.json","markdown":"https://secwatch.observer/filing/0001104659-25-084053.md","text":"https://secwatch.observer/filing/0001104659-25-084053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/0001104659-25-084053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/tm2524511d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:37:04.920671+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d1742707c40cdbd64040c8c198df1c7861c870b0","claim":"NOVAVAX INC incurred convertible notes of $225.0 million aggregate principal amount with The Bank of New York Mellon Trust Company, N.A. at 4.625% per annum maturing September 1, 2031.","evidence_excerpt":"On August 27, 2025, Novavax, Inc. (the “Company”) consummated (the “Closing”) the previously announced privately negotiated exchange and subscription transactions, pursuant to which it issued $225.0 million aggregate principal amount of its 4.625% Convertible Senior Notes due 2031 (the “Notes”)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/0001104659-25-084053-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$225.0 million aggregate principal amount"},{"label":"Counterparty","value":"The Bank of New York Mellon Trust Company, N.A."},{"label":"Rate","value":"4.625% per annum"},{"label":"Maturity","value":"September 1, 2031"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}